Home 2021

Enzyme replacement therapy

Gene Therapy for ADA-SCID Still Benefitting Patients after Two to Three Years
Genome Editing

Gene Therapy for ADA-SCID Still Benefitting Patients after Two to Three Years

Kevin Mayer -
0
Sangamo Shares Plunge after Interim Results for MPS Candidates Fall Short of Clinical Benefit
Featured

Sangamo Shares Plunge after Interim Results for MPS Candidates Fall Short of Clinical Benefit

Alex Philippidis -
0
Gene Therapy for Rare Diseases
Insights

Gene Therapy for Rare Diseases

Sue Pearson -
0
FDA Approves Ultragenyx Enzyme Replacement Therapy for MPS VII
Industry News

FDA Approves Ultragenyx Enzyme Replacement Therapy for MPS VII

GEN Staff Writer -
0
Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year
Cancer

Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year

GEN Staff Writer -
0
mRNA: Addressing the Blind Spot of Enzyme Replacement Therapy
Insights

mRNA: Addressing the Blind Spot of Enzyme Replacement Therapy

Michael Houston -
0
Protalix Sells Share of ELELYSO Collaboration, Equity Stake to Pfizer
Drug Discovery

Protalix Sells Share of ELELYSO Collaboration, Equity Stake to Pfizer

GEN Staff Writer -
0
AbbVie, Shire Call Off $51.7B Merger
Industry News

AbbVie, Shire Call Off $51.7B Merger

GEN Staff Writer -
0
ArmaGen Licenses AGT-182 Rights to Shire for Up to $225M
News

ArmaGen Licenses AGT-182 Rights to Shire for Up to $225M

GEN Staff Writer -
0
The High Cost of Rare Disease Drugs
Insights

The High Cost of Rare Disease Drugs

Alex Philippidis -
3
1234Page 1 of 4
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.